Delving into the Latest Updates on Teva Takeda Pharma Ltd. with Synapse

概览

疾病领域	数量

神经系统疾病	7
感染	4
免疫系统疾病	3
内分泌与代谢疾病	3
肿瘤	1

排名前五的药物类型	数量

小分子化药	10
中药	1
合成多肽	1

排名前五的靶点	数量

PBPs(细菌青霉素结合蛋白家族)	3
PBPs x β-lactamase	1
GABAA receptor(γ-氨基丁酸A受体)	1
RARs x RXRs	1
TRHR(促甲状腺素释放激素受体)	1

关联

12

项与 Teva Takeda Pharma Ltd. 相关的药物

Glatiramer Acetate

醋酸格拉默

靶点-

作用机制

免疫调节剂

在研机构

Consegna Pharma, Inc.初创企业 [+8]

原研机构

Weizmann Institute of Science

在研适应症

多发性硬化症 [+6]

非在研适应症

肌萎缩侧索硬化

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1996-12-20

Cefozopran Hydrochloride

盐酸头孢唑兰

靶点

PBPs

作用机制

PBPs抑制剂 [+1]

在研机构

Teva Takeda Yakuhin Ltd. [+1]

原研机构

Takeda Pharmaceutical Co., Ltd.

在研适应症

细菌感染 [+16]

非在研适应症

（非特异性）化脓性脑膜炎 [+10]

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期1995-08-01

Chimaphila umbellata extract/Populus tremula extract/Pulsatilla pratensis mill extract/Equisetum arvense extract/Wheat Germ Oil

靶点-

作用机制-

在研机构

Nichi-Iko Gifu Plant Co., Ltd. [+1]

原研机构

Nichi-Iko Gifu Plant Co., Ltd.

在研适应症

前列腺增生症

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期1994-03-15

1

项与 Teva Takeda Pharma Ltd. 相关的临床试验

NCT03209479 / CompletedN/A

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

The purpose of this study is to evaluate the safety and efficacy of Copaxone subcutaneous injection syringe (hereinafter referred to as Copaxone) in patients with multiple sclerosis in the routine clinical setting.

开始日期2015-11-24

申办/合作机构

Teva Takeda Pharma Ltd.初创企业

[+1]

100 项与 Teva Takeda Pharma Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Teva Takeda Pharma Ltd. 相关的专利（医药）

登录后查看更多信息

64

项与 Teva Takeda Pharma Ltd. 相关的文献（医药）

2021-08-03·Current Medical Research and Opinion4区 · 医学

Treatment patterns following initiation of generic glatiramer acetate among patients with multiple sclerosis from two large real-world databases in the United States

4区 · 医学

Article

作者: Alexander, Jessica K. ; Vardi, Michaela ; Su, Zhaohui ; Wu, Ying ; Bryant, Allison ; Hulbert, Erin ; Kasturi, Jyotsna ; Ariely, Rinat

INTRODUCTIONTo better understand treatment patterns in US patients with multiple sclerosis (MS) initiating generic glatiramer acetate (GA), this study examined adherence, discontinuation and switching patterns from generic follow-on glatiramer acetate (FOGA) therapy in real-world patient cohorts.METHODSRetrospective analyses utilized data from two large US databases (administrative claims and linked electronic medical records). Eligible adult MS patients had ≥1 pharmacy claim for FOGA during the identification period; the first FOGA claim was the index date. All analyses were descriptive; proportion of days covered (PDC) was calculated as a measure of adherence to FOGA during the follow-up period.RESULTSThe first cohort consisted of 95 patients, with 93.6% having a branded GA claim for Copaxone during the baseline period. Half these patients (48.4%) had high adherence to FOGA therapy (PDC: 0.8-1.0). Fifty-five patients (57.9%) initially discontinued FOGA with a mean persistence of 112 days. Of those who discontinued, 7.3% had no subsequent disease-modifying therapy (DMT), 30.9% restarted FOGA and 61.8% did not restart FOGA. The second cohort consisted of 1957 patients, with 63.8% having a branded GA claim for Copaxone during the baseline period and 33.5% were treatment naïve. The majority of patients (61.9%) had high adherence to FOGA therapy. A total of 1597 patients (81.6%) initially discontinued FOGA with a mean persistence of 93 days. Of those who discontinued, 55.8% switched to another DMT, 16.7% restarted FOGA and 37.5% had no subsequent DMT.CONCLUSIONAdherence to FOGA therapy was reasonably high across cohorts; however, most patients discontinued their initial FOGA within four months of the index date and most switches from FOGA were to branded GA products.

2020-08-01·Kidney International Reports3区 · 医学

Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis

3区 · 医学

ArticleOA

作者: Sedor, John R ; Rovin, Brad H ; Willette, Robert N ; McMahon, Alan ; Barbour, Sean J ; Paglione, Marcella ; Holland, M Claire ; Ross Terres, Jorge Alfonso ; Sprecher, Dennis L ; Nachman, Patrick H ; Thorneloe, Kevin S ; Jennette, J Charles ; Gipson, Debbie S ; Lafayette, Richard ; Vallow, Sue ; Gao, Feng ; Hladunewich, Michelle A

INTRODUCTIONIdiopathic focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome and end-stage renal disease. In preclinical models and biopsies of human FSGS kidneys, p38 mitogen-activated protein kinase (MAPK) has demonstrated enhanced activity; and p38 MAPK inhibition has improved disease markers. This proof-of-concept trial aimed to assess efficacy, safety, tolerability, and pharmacokinetics of losmapimod, an oral p38 MAPK inhibitor, in humans with FSGS.METHODSA single-arm, multicenter, open-label, Phase II trial (NCT02000440) was conducted in adults with FSGS; proteinuria ≥2.0 g/d; estimated glomerular filtration rate (eGFR) ≥45 ml/min per 1.73 m²; blood pressure <140/90 mm Hg. Collapsing and genetic forms of FSGS were excluded. The primary endpoint was number of patients with ≥50% proteinuria reduction and eGFR ≥70% of baseline after receiving losmapimod twice-daily for 16 to 24 weeks.RESULTSSeventeen patients received ≥1 losmapimod dose. No patients achieved the primary endpoint; therefore, the study was terminated following a prespecified interim analysis. At week 24, proteinuria reductions between 20% and <50% were observed in 4 patients and proteinuria increases >20% in 3 patients. One patient achieved a proteinuria response (≥50% reduction) at week 2 but subsequently relapsed. Losmapimod pharmacokinetics were consistent with prior studies. No serious adverse events (AEs) were reported.CONCLUSIONp38 MAPK inhibition with losmapimod did not result in ≥50% reduction of proteinuria in patients with FSGS. However, study population heterogeneity may have contributed to our negative findings and therefore this does not eliminate the potential to demonstrate benefit in a population more sensitive to p38 MAPK inhibition if identifiable in the future by precision-medicine methods.

2020-07-15·Nature Reviews Neurology1区 · 医学

Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities

1区 · 医学

Review

作者: Iadarola, Michael J ; Scholz, Joachim ; Aghaeepour, Nima ; Pelleymounter, Mary Ann ; Crean, Christopher ; Mackey, Sean ; Iyengar, Smriti ; Edwards, Robert ; Brenton, Ashley ; Jiang, Yunyun ; Davis, Karen D ; Tracey, Irene ; Ahn, Andrew H ; Wang, Jing ; Segerdahl, Marta ; Gaudilliere, Brice ; Burczynski, Michael E ; Saab, Carl Y ; Sang, Christine N ; Wager, Tor D ; Wasan, Ajay D ; Kong, Jiang-Ti ; Borsook, David ; Angst, Martin S ; Hergenroeder, Georgene W ; Veasley, Christin

Pain medication plays an important role in the treatment of acute and chronic pain conditions, but some drugs, opioids in particular, have been overprescribed or prescribed without adequate safeguards, leading to an alarming rise in medication-related overdose deaths. The NIH Helping to End Addiction Long-term (HEAL) Initiative is a trans-agency effort to provide scientific solutions to stem the opioid crisis. One component of the initiative is to support biomarker discovery and rigorous validation in collaboration with industry leaders to accelerate high-quality clinical research into neurotherapeutics and pain. The use of objective biomarkers and clinical trial end points throughout the drug discovery and development process is crucial to help define pathophysiological subsets of pain, evaluate target engagement of new drugs and predict the analgesic efficacy of new drugs. In 2018, the NIH-led Discovery and Validation of Biomarkers to Develop Non-Addictive Therapeutics for Pain workshop convened scientific leaders from academia, industry, government and patient advocacy groups to discuss progress, challenges, gaps and ideas to facilitate the development of biomarkers and end points for pain. The outcomes of this workshop are outlined in this Consensus Statement.

100 项与 Teva Takeda Pharma Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Teva Takeda Pharma Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

12

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

醋酸格拉默	多发性硬化症更多	批准上市
头孢哌酮钠/舒巴坦钠 ( PBPs x β-lactamase )	感染更多	批准上市
盐酸头孢唑兰 ( PBPs )	腹膜炎更多	批准上市
艾司唑仑 ( GABAA receptor )	入睡和睡眠障碍更多	批准上市
普罗瑞林 ( TRHR )	意识障碍更多	批准上市